[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07379138":3,"trial-entities:NCT07379138":135,"trial-summary:NCT07379138":138},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":21,"phases":22,"enrollment_info":24,"interventions":27,"primary_outcomes":55,"secondary_outcomes":69,"sex":91,"minimum_age":92,"maximum_age":15,"healthy_volunteers":93,"eligibility_criteria":94,"std_ages":101,"locations":104,"central_contacts":126,"overall_officials":128,"references":130,"see_also_links":131},"NCT07379138","25-007199","Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients","Launching the Era of Melanoma Survivorship: Defining Benchmarks in Quality of Life Inclusive of Mental Health (QOL-MH)","RECRUITING","2031-12-31","2026-06","2026-06-22","2025-12-10","Mayo Clinic","OTHER",null,"This clinical trial studies how people feel and live during the first two years after being treated for melanoma and whether cognitive behavioral therapy for cancer distress (CBT-C) works to improve quality of life in patients with stage III-IV melanoma. The melanoma survivorship population is rapidly growing, given the increasing survival rates due to treatment advancements. An urgent need to better define and optimize comprehensive quality of life inclusive of mental health (QOL-MH) has been identified. Cognitive behavioral therapy is a type of psychotherapy that helps patients change their behavior by changing the way they think and feel about certain things. CBT-C is a new type of care that helps patients cope with cancer-related stress, which can include problems like trouble sleeping, trouble focusing, or changes in social life and daily activities. Gathering information on how melanoma patients feel and live during the first two years after treatment may help promote improved care and continued scientific advancements in the understanding of melanoma specific QOL-MH and survivorship as a whole, and may also help determine whether CBT-C improves qualify of life in patients with stage III-IV melanoma.",[18],"Melanoma",[],"INTERVENTIONAL","SUPPORTIVE_CARE",[23],"NA",{"count":25,"type":26},350,"ESTIMATED",[28,36,46,51],{"type":14,"name":29,"description":30,"armGroupLabels":31,"otherNames":33},"Best Practice","Receive SOC",[32],"Aim 2 arm II (SOC)",[34,35],"standard of care","standard therapy",{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":42},"BEHAVIORAL","Cognitive Behavior Therapy","Attend CBT-C sessions",[41],"Aim 2 arm I (CBT-C)",[43,44,45],"CBT","cognitive therapy","CT",{"type":14,"name":47,"description":48,"armGroupLabels":49},"Electronic Health Record Review","Ancillary studies",[50,41,32],"Aim 1 (QOL-MH)",{"type":14,"name":52,"description":53,"armGroupLabels":54},"Questionnaire Administration","Complete QOL-MH questionnaires",[50,41,32],[56,60,63,66],{"measure":57,"description":58,"timeFrame":59},"Change in FACT-M total score (Aim 1)","The Functional Assessment of Cancer Therapy - Melanoma (FACT-M) is a 52-item questionnaire used to measures quality of life (QoL) in melanoma cancer patients. Responses to each item are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much). Scores range from 0-108 with higher scores indicating better quality of life. For this study, 8 items have been omitted, so the number of items is 44, with total scores ranging from 0-176. Descriptive statistics will be used to tabulate and graph the observed total scores and the change from baseline total scores over time.","Baseline (at enrollment) and 3, 6, 9, 12, 18, and 24 months",{"measure":61,"description":62,"timeFrame":59},"Change in FACT-ICM total score (Aim 1)","The Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator (FACT-ICM) is a 25-item subscale that measures symptom burden and health-related quality of life (HRQoL) over the past 7 days in patients receiving immune checkpoint inhibitors. Responses to each question are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much). Scores range from 0-100 with higher scores indicating greater symptom burden and poorer quality of life. Descriptive statistics will be used to tabulate and graph the observed total scores and the change from baseline total scores over time.",{"measure":64,"description":65,"timeFrame":59},"Change in Impact of Events Scale-Revised (IES-R) score (Aim 1)","The Impact of Event Scale-Revised (IES-R) is a 22-item self-report measure designed to assess subjective distress related to stressful life events. The IES-R consists of 22 items for which participants rate how distressing each difficulty has been during the past 7 days with regard to their cancer diagnosis. Responses are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Extremely). Scores range from 0-88 with higher scores indicating greater distress. Descriptive statistics will be used to tabulate and graph the observed total scores and the change from baseline total scores over time.",{"measure":67,"description":68,"timeFrame":59},"Change in IES-R score (Aim 2)","The Impact of Event Scale-Revised (IES-R) is a 22-item self-report measure designed to assess distress related to stressful life events. The IES-R consists of 22 items which participants rate distress over the past 7 days with regard to their cancer diagnosis. Responses are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Extremely). Scores range from 0-88 with higher scores indicating greater distress.",[70,73,76,79,82,85,88],{"measure":71,"description":72,"timeFrame":59},"Change in PHQ-8 score","The Patient Health Questionnaire-8 (PHQ-8) is a brief, self-report tool used to screen for and measure the severity of depression by asking about 8 depressive symptoms over the past two weeks, scoring from 0 (not at all) to 3 (nearly every day) for each, with total scores indicating severity (e.g., 0-4 minimal, 10-14 moderate) and a score of 10 or more often suggesting major depression.",{"measure":74,"description":75,"timeFrame":59},"Change in GAD-7 Anxiety score","The General Anxiety Disorder 7-item (GAD-7) scale is used to assess symptoms and feelings of anxiety over the past two weeks. The GAD-7 consists of 7 questions answered on a scale of 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 21 where 0 indicates no anxiety, 1-4 indicates minimal anxiety, 5-9 indicates mild anxiety, 10-14 indicates moderate anxiety, and 15-21 indicates severe anxiety. If patients indicate any problems they are asked to indicate how difficult the problems have made daily life: not difficult at all, somewhat difficult, very difficult, or extremely difficult.",{"measure":77,"description":78,"timeFrame":59},"Change in PSQI score","The Pittsburgh Sleep Quality Index (PSQI)measures the severity of sleep disturbances. Possible scores range from 0 to 21 with higher scores indicating a worse outcome\u002Fmore severe symptoms of sleep disturbance.",{"measure":80,"description":81,"timeFrame":59},"Change in PROMIS: Fatigue score","The Patient-Reported Outcomes Measurement Information System (PROMIS): Fatigue questionnaire, a subscale of the PROMIS-29, measures fatigue and related symptoms over the past seven days. It consists of four items rated on a scale of 1(not at all) to 5 (very much). A higher score indicates greater experience of fatigue.",{"measure":83,"description":84,"timeFrame":59},"Change in PROMIS: Pain Interference score","The PROMIS: Pain Interference questionnaire, a subscale of the PROMIS-29, is used to assess pain interference in daily life over the past seven days. It consists of four items rated on a scale of 1(not at all) to 5 (very much). A higher score indicates greater levels of pain interference.",{"measure":86,"description":87,"timeFrame":59},"Change in COST-FACIT score","The Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COSTFACIT) measures financial toxicity among cancer patients. This measure reflects five themes of financial toxicity which include: financial, resource, affect, coping, and effect on family. It consists of 12 questions, each answered on a scale of 0 (not at all) to 5 (very much), with higher scores indicating greater financial toxicity.",{"measure":89,"description":90,"timeFrame":59},"Change in MEPS score","The Medical Expenditures Survey (MEPS) measures the financial impact of cancer, its treatment, or the lasting effects of that treatment. It consists of 5 multiple choice questions, including free text\u002F \u002F fill-in options where appropriate. Results are reported descriptively. .","ALL","18 Years",false,{"inclusion":95,"exclusion":99,"raw_text":100},[96,97,98],"Age \\>= 18-years","Stage III-IV melanoma and =\\\u003C 2 month duration of this diagnosis","Able to read English sufficient to complete survey, informed consent",[],"Inclusion Criteria:\n\n* Age \\>= 18-years\n* Stage III-IV melanoma and =\\\u003C 2 month duration of this diagnosis\n* Able to read English sufficient to complete survey, informed consent\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria",[102,103],"ADULT","OLDER_ADULT",[105],{"facility":106,"status":8,"city":107,"state":108,"zip":109,"country":110,"contacts":111,"geoPoint":123},"Mayo Clinic in Rochester","Rochester","Minnesota","55905","United States",[112,117,120],{"name":113,"role":114,"phone":115,"email":116},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":118,"role":114,"phone":119},"Deanna Hofschulte","507-255-2972",{"name":121,"role":122},"Shawna L. Ehlers, PhD, LP","PRINCIPAL_INVESTIGATOR",{"lat":124,"lon":125},44.02163,-92.4699,[127],{"name":113,"role":114,"phone":115,"email":116},[129],{"name":121,"affiliation":13,"role":122},[],[132],{"label":133,"url":134},"Mayo Clinic Clinical Trials","https:\u002F\u002Fwww.mayo.edu\u002Fresearch\u002Fclinical-trials",{"nct_id":4,"conditions":136,"biomarkers":137},[18],[],{"nct_id":4,"found":139,"summary":140,"prompt_version":150},true,{"design":141,"status":142,"heading":143,"summary":144,"follow_up":145,"word_count":146,"commitments":147,"compensation":148,"drugs_mentioned":149},"This interventional study plans to enroll 350 participants. It is not specified if it is randomized or blinded.","completed","Studying Quality of Life and CBT for Melanoma Patients","This study is looking at how people with advanced melanoma (stage III-IV) feel and live during the first two years after their diagnosis. It aims to see if a type of talk therapy called Cognitive Behavioral Therapy for Cancer Distress (CBT-C) can improve their overall quality of life, including their mental health. As more people are surviving melanoma due to new treatments, understanding and improving their well-being is very important. CBT-C helps you change how you think and feel about things to improve your behavior. You might be able to join if you are at least 18 years old, have stage III-IV melanoma diagnosed within the last two months, and can read English. The study plans to enroll 350 participants, but its current recruitment status is unclear.","Your quality of life and mental health will be tracked for up to 24 months after enrollment.",127,"You would complete questionnaires about your quality of life and mental health at the start of the study, and then at 3, 6, 9, 12, 18, and 24 months. Some participants will also attend CBT-C sessions.","Not stated in the trial record.",[],"v2"]